European Medicines Agency

EMA has recommended the first oral GLP-1 treatment for weight management, offering an alternative to weekly injections. This treatment can be used, together with diet and physical activity, in adults with obesity, or who are overweight and have at least one weight-related condition. It will only be available with a prescription.   Read more 👉 https://lnkd.in/ewqkQFPa

📢Our human medicines committee, the CHMP, recommended 8 new medicines for approval in the EU, including the first medicine to treat rare uncontrolled growth of body tissues and a medicine for two types of pulmonary fibrosis. The CHMP also recommended an extension to the marketing authorisation of the first glucagon-like peptide (GLP-1) receptor agonist for weight management developed for oral use. Read more in the highlights published today 🔗https://lnkd.in/eGCZGPfT

How are new medicines developed and approved? 💊 Our latest video explains the role of clinical trials in testing the safety and effectiveness of medicines in the EU. Learn about the different trial phases, how patients contribute to research, and why clinical trials are essential for advancing healthcare. Watch the full video here: https://lnkd.in/ekcayiNb With Begonya Nafría Escalera, Joel Passarinho, Helle Christiansen, and Denis Lacombe.

📢 EU tracks early progress towards 2030 clinical trial targets   With the European Commission and the Heads of Medicines Agencies (HMA), we have published the first report tracking progress against the EU’s new clinical trial targets in the European Union. These targets aim to strengthen the EU position as a leading destination for clinical research while improving patients’ timely access to innovative medicines. Key takeaways between 1 January -31 March 2026: ✅ More multinational trials – 19 additional trials have been authorised in addition to the historical average (target: +500 by 2030). ✅ Faster recruitment timelines – 40.5% of trials recruit participants within 200 days from application submission (target: 66% by 2030).   👉 Read more in our news announcement: https://lnkd.in/ejxEr8hy

🎉Great news: together with partner EU agencies, we have been nominated for a European Ombudsman Award.   The nomination recognises the joint Instagram channel @OneHealth_EU, run together by European Food Safety Authority (EFSA), European Environment Agency, European Chemicals Agency, European Medicines Agency, European Centre for Disease Prevention and Control (ECDC) and EU Health and Food Safety. This channel aims to make science, health, environmental and safety topics more accessible, especially for younger audiences.    Take a look at all the inspiring projects and vote project 21 before 15 June: 👉 https://lnkd.in/drCndgnG     #OneHealthEU #EOAward!

There are currently no authorised antiviral treatments or vaccines for #hantavirus. Clinical management relies on supportive care and timely access to critical care facilities. We at EMA stand ready to support the development and regulatory evaluation of vaccines and therapeutics for hantaviruses. We also caution against misinformation circulating online that falsely links hantavirus infection to COVID‑19 vaccination. Such claims are not supported by scientific evidence. Read more in our news announcement: https://lnkd.in/epq3WzSs

The European Medicines Agency welcomes the political agreement on the Critical Medicines Act, a major step toward stronger, more resilient supply chains for critical medicines in the EU.   The CMA will reinforce manufacturing capacity, address supply chain vulnerabilities, and support better access to essential medicines. EMA is already advancing this work by assessing supply chain vulnerabilities of essential medicines and expanding the European Shortages Monitoring Platform.   We look forward to supporting implementation with the European Commission and EU Member States. Find out more about the CMA: https://lnkd.in/eq6zfKvJ EU Health and Food Safety

Before any medicine reaches patients in the EU, it goes through a thorough scientific evaluation. What does that actually involve? Our full-length video gives you a closer look at the role of experts from the Committee for Medicinal Products for Human Use (CHMP) and how they assess whether a medicine’s benefits outweigh its risks. 🎥 Watch now to see how decisions are made to protect public health across Europe.